Sign In
Buy CRBU
$2.00
-0.320 (-13.79%)
At Close: Jun 03, 2026
Caribou Biosciences: 2 Clinical Data Updates In 2024 Could Bring Value
01:59pm, Thursday, 18'th Apr 2024
Caribou Biosciences, Inc. is expected to produce results from phase 1 ANTLER study, using CB-010 for the treatment of 2nd-line large B-cell lymphoma patients, at medical meeting Q2 of 2024. Initial do
BERKELEY, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced an abstract on
Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus
04:00pm, Thursday, 04'th Apr 2024
-- FDA has cleared Caribou's IND application for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 -- -- Driven by encouraging initial safet
NEW YORK--(BUSINESS WIRE)---- $CRBU #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of HireRight Holdings Corp. (“Hir
All You Need to Know About Caribou Biosciences, Inc. (CRBU) Rating Upgrade to Buy
01:01pm, Thursday, 14'th Mar 2024
Caribou Biosciences, Inc. (CRBU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Why Caribou Biosciences Stock Is Crashing Today
12:37pm, Tuesday, 12'th Mar 2024
Caribou Biosciences announced that it has paused the development of experimental cell therapy CB-020. The company still has three programs in clinical testing.
Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
04:05pm, Monday, 11'th Mar 2024
-- 30 th patient dosed in CB-010 ANTLER Phase 1 trial dose expansion; initial dose expansion data and RP2D to be disclosed in Q2 2024 -- -- 1 st patient dosed in CB-012 AMpLify Phase 1 trial for patie
Caribou Biosciences to Participate in Upcoming Investor Conferences
04:05pm, Thursday, 15'th Feb 2024
BERKELEY, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company's
2 Risky Gene-Editing Stocks to Buy in the New Bull Market if You Dare
08:30am, Monday, 12'th Feb 2024
There's a new bull market, and it's lifting biotech stocks once again. Caribou Biosciences already has some good data and regulatory buy-in.
3 Biotech Stocks You Can Buy and Hold for the Next Decade
08:45am, Monday, 15'th Jan 2024
Catalyst buys appealing medicines or pharmaceutical assets and gets them out the door. Recursion uses AI and vast biomedical data to discover and exploit leads for new drugs.
Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024
11:00am, Sunday, 07'th Jan 2024
-- Tim Kelly to lead Caribou's technical operations strategy and execution -- -- CB-010 ANTLER Phase 1 trial initial dose expansion data and RP2D to be disclosed Q2 2024; Caribou plans to initiate piv
3 Gene-Editing Stocks With the Potential to Mint Millionaires
05:20am, Wednesday, 13'th Dec 2023
Gene editing stocks have received a lot of attention throughout 2023. The intense focus on gene editing therapies and CRISPR technology is likely only to increase moving forward: The U.S. Food and Dru
Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024
04:02pm, Tuesday, 12'th Dec 2023
-- Caribou met with the FDA and reached alignment on a pivotal trial in 2L LBCL with CB-010 versus a comparator arm of immunochemotherapy followed by HDCT and ASCT -- -- ANTLER Phase 1 trial continues
Caribou Biosciences, Inc. (CRBU) Upgraded to Buy: What Does It Mean for the Stock?
01:32pm, Friday, 08'th Dec 2023
Caribou Biosciences, Inc. (CRBU) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Next-Gen Biotech: 3 Companies Leading the Charge in Gene Therapy
05:15am, Thursday, 07'th Dec 2023
Using gene therapy, companies can change patients' DNA. One type of gene therapy, called CRISPR, largely mimics a method used by bacteria to fend off viruses.
